NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Peptide testing

Ordered peptides from Bfflist AMO? Mail in a sample (US only) and let us test it.

Test my supply
72%
Finnrick rating
#284 of 489 ranked vendors
55 of 74 classifiable tests passed
methodology · Purity focus
Finnrick analysis

Bfflist AMO's purity-focus record is led by a deeper Retatrutide file, where later tests look steadier after earlier fill and purity volatility, while Tirzepatide shifted from a clean streak to recent misses. Cagrilintide is the weak spot with repeated purity/fill failures and same-batch volatility, and Semaglutide remains uncertain on thin mixed evidence.

methodology →
vendor intelligence report
Vendor Intelligence Report: Bfflist AMO

The report maps the AmoPeptide-to-BFF Chem domain chain, an inaccessible EC21 corporate anchor, and a reachable Telegram handle displaying an operator alias. It also separates current storefront status, payment rails, and brand-confusion risk.

30 pages6 risk factors assessed2 Jul 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
Retatrutide
$0.63
87%
48
2
Tirzepatide
$0.36
70%
17
4
Cagrilintide
$1.56
43%
6
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%29 Dec 2025: 69%29 Dec 2025: 70%1 Jan 2026: 70%7 Jan 2026: 70%7 Jan 2026: 71%7 Jan 2026: 71%15 Jan 2026: 71%15 Jan 2026: 72%15 Jan 2026: 72%22 Jan 2026: 72%22 Jan 2026: 72%22 Jan 2026: 72%22 Jan 2026: 71%26 Jan 2026: 72%26 Jan 2026: 72%26 Jan 2026: 72%29 Jan 2026: 73%29 Jan 2026: 73%29 Jan 2026: 73%29 Jan 2026: 72%2 Feb 2026: 72%4 Feb 2026: 72%11 Feb 2026: 72%11 Feb 2026: 72%13 Feb 2026: 73%15 Feb 2026: 73%16 Feb 2026: 73%16 Feb 2026: 74%18 Feb 2026: 74%18 Feb 2026: 73%18 Feb 2026: 72%18 Feb 2026: 71%18 Feb 2026: 72%18 Mar 2026: 71%21 Mar 2026: 72%29 Mar 2026: 72%21 Apr 2026: 72%23 Apr 2026: 71%15 Jul 2026: 71%6 Oct 2026: 71%10 Nov 2026: current 72%69%72%72%Dec 25Nov 26
Peptide testing

Ordered peptides from Bfflist AMO? Mail in a sample (US only) and let us test it.

Test my supply
Bfflist AMO test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
6 Oct 2026
Pass
Tirzepatide
lab nameView COA
15 Jul 2026
Pass
Retatrutide
lab nameView COA
23 Apr 2026
Fail
Tirzepatide
lab nameView COA
21 Apr 2026
Pass
Retatrutide
lab nameView COA
29 Mar 2026
Pass
Retatrutide
lab nameView COA
21 Mar 2026
Pass
Cagrilintide
lab nameView COA
18 Mar 2026
Fail
Cagrilintide
lab nameView COA
18 Feb 2026
Fail
Tirzepatide
lab nameView COA
18 Feb 2026
Fail
Tirzepatide
lab nameView COA
18 Feb 2026
Fail
Tirzepatide
lab nameView COA
1-10 of 74

About Bfflist AMO test results from Finnrick

Bfflist AMO is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 4 peptides and 74 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Bfflist AMO peptides in this dataset are Cagrilintide (6 tests), Retatrutide (48 tests) and Semaglutide (3 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 74 recent tests. It also includes 1 correction related to this vendor.

Corrections
2025-11-05
Lab correction
These were remade and reanalyzed by Lab G. They traced the discrepancy to a likely human error during preparation.
Peptide testing

Ordered peptides from Bfflist AMO? Mail in a sample (US only) and let us test it.

Test my supply